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ABSTRACT
Friedreich ataxia (FRDA) is caused by hyperexpan-
sion of GAA TTC repeats located in the first intron
of the FXN gene, which inhibits transcription leading
to the deficiency of frataxin. The FXN gene is an
excellent target for therapeutic intervention since
(i) 98% of patients carry the same type of mutation,
(ii) the mutation is intronic, thus leaving the FXN
coding sequence unaffected and (iii) heterozygous
GAA TTC expansion carriers with ~50% decrease
of the frataxin are asymptomatic. The discovery of
therapeutic strategies for FRDA is hampered by
a lack of appropriate molecular models of the dis-
ease. Herein, we present the development of a new
cell line as a molecular model of FRDA by insert-
ing 560 GAA TTC repeats into an intron of a GFP
reporter minigene. The GFP_(GAA TTC)560 minigene
recapitulates the molecular hallmarks of the
mutated FXN gene, i.e. inhibition of transcription of
the reporter gene, decreased levels of the reporter
protein and hypoacetylation and hypermethyla-
tion of histones in the vicinity of the repeats.
Additionally, selected histone deacetylase inhibi-
tors, known to stimulate the FXN gene expression,
increase the expression of the GFP_(GAA TTC)560
reporter. This FRDA model can be adapted to
high-throughput analyses in a search for new ther-
apeutics for the disease.
INTRODUCTION
Friedreich ataxia (FRDA), a severe autosomal recessive
neurodegenerative disease, is the most frequent inherited
ataxia with a prevalence of one in 30000–50000
Caucasians (1,2). FRDA is caused by hyperexpansion of
GAA TTC repeats in the ﬁrst intron of the FXN gene.
Normal alleles contain <30 triplets while disease-causing
expanded FXN alleles have from 66 to  1700 GAA TTC
repeats (1,3,4). The elongated GAA TTC sequence sup-
presses the expression of the FXN gene, causing a deﬁ-
ciency of frataxin that leads to a serious imbalance in
mitochondrial iron metabolism (5). The amount of fra-
taxin detected in FRDA patient cells varies between 5%
and 30% of the frataxin level found in unaﬀected indi-
viduals (1,6–8). Since the coding sequence of the FXN
gene in FRDA patients does not carry mutations, alleviat-
ing the transcriptional block imposed by the trinucleotide
repeats is an attractive target for therapeutic intervention.
Importantly, asymptomatic, heterozygous carriers of the
GAA TTC expansion have  40–50% of normal levels of
FXN mRNA and protein concentrations (8,9). Hence, an
increase in frataxin expression to levels found in carriers
or even a modest enhancement of frataxin production may
have a therapeutic eﬀect.
Two major mechanisms of transcription inhibition by
long GAA TTC repeats have been postulated (10–12).
First, the expanded GAA TTC repeats can adopt non-B
DNA structures such as triplexes, bitriplexes and/or sticky
DNA (13–17) as well as stable DNA RNA hybrid confor-
mations (18–20). These structures can aﬀect many aspects
of DNA metabolism such as replication, recombination
and genome stability (12). Long tracts of GAA TTC
were demonstrated to inhibit transcription in vitro and
in cell cultures (14,18,19,21). Second, recent studies sug-
gest that FXN gene silencing is induced by expanded
GAA TTC repeats via chromatin modiﬁcations that are
characteristic of heterochromatin (9,22–24). Heterochro-
matin hallmarks such as reduced level of histone H3 and
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tion of lysine 9 in histone H3, were especially apparent
immediately downstream and upstream of an expanded
repeat tract, whereas the FXN promoter did not show
signiﬁcant chromatin alterations (9,23–25).
A limited number of molecules that reverse transcrip-
tional silencing of the FXN have been described (10,11,26).
Research in the ﬁeld of FRDA therapeutics is substan-
tially hampered by a lack of appropriate models of
expanded GAA TTC alleles for screening compound
libraries or approved drugs. Current methods of monitor-
ing changes in frataxin mRNA and protein expression,
based predominantly on quantitative PCR and western
blots, are laborious and ineﬃcient, especially for high-
throughput applications. Additionally, low levels of the
FXN mRNA and frataxin present in the FRDA cells
make the quantitative analyses diﬃcult and error-prone.
Several human lymphoblast cell lines, derived from
FRDA patients and the expansion carriers, are currently
available. Studies related to pathogenesis of FRDA have
also been conducted using primary lymphocytes derived
from patients as well as using RNAi-induced frataxin
knockdown cells (9,27,28). Although existing cell-based
models are valuable for discovering new aspects of
FRDA pathogenesis and for evaluating the eﬃcacy
of pre-selected compounds that act on the endogenous
FXN gene, they are not adequate for high-throughput
analyses. Two reporter FRDA cell lines designed for com-
pound screening have been described (29,30). Due to
either short GAA TTC repeats and/or their location
within the reporter construct, neither of these cell lines
fully recapitulates the molecular defects of endogenous
expanded FXN genes.
To accelerate the discovery of new FRDA therapeutics
and to study the molecular pathways involved in repeat-
induced gene silencing, we designed, constructed and vali-
dated a cell line containing a GFP reporter minigene with
an intronic (GAA TTC)560 tract. This reporter construct
recapitulates many of the characteristics of the endogen-
ous expanded FXN gene such as reduced mRNA and pro-
tein levels, patterns of chromatin modiﬁcations, and
repeat instability. Expression of the minigene is stimulated
by compounds known to increase levels of frataxin in cells
from FRDA patients. This molecular model of FRDA can
be utilized in high-throughput screening of large com-
pound libraries in a search for new pharmacological
agents with potential therapeutic beneﬁts in FRDA.
MATERIALS AND METHODS
Construction of theGFP_(GAA TTC) cell lines
pRW5656, a derivative of pcDNA5/FRT/TO (Invitrogen),
was constructed by cloning the GFP gene containing the
adenovirus exon (Ad2) from pGFP-Ad2_wt (31) into the
NotI/KpnI sites of the vector. Subsequently, a polylinker,
containing Bsu36I and BssHII recognition sequences,
was cloned into the XcmI site of the intron followed
by removal of the Ad2 exon by PmlI and EcoRV diges-
tion, creating pGFP_Int.
pRW3823 (13) was a source of the (GAA TTC)270 tract
while the longest sequence (560 GAA TTC repeats) was
obtained using PCR from genomic DNA isolated from
the GM16210 cell line (NIGMS Human Genetic Cell
Repository at The Coriell Institute for Medical
Research, Camden, NJ, USA). Long GAA TTC tracts
were ampliﬁed as described (1). A cell line harboring
(GAA TTC)70 repeats was a product of spontaneous
repeat deletion, which occurred most likely during inte-
gration of a plasmid containing 560 repeats into the
HEK293Flp-InT-Rex cells (Invitrogen). The plasmid
DNA as well as the PCR product were cleaved by Bsu36I
and BssHII endonucleases (recognition sites are present in
the sequences ﬂanking the repeats in the intron 1 of the
FXN gene) and ligated into the Bsu36I/BssHII cleaved
pGFP_Int. Plasmids containing full-length GAA TTC
repeats as determined using polyacrylamide gel electro-
phoresis of the excised inserts were site speciﬁcally
integrated into the genome of HEK293Flp-InT-Rex
cells (Invitrogen) creating four cell lines containing the
GFP minigene: GFP_(GAA TTC)0, GFP_(GAA TTC)70,
GFP_(GAA TTC)270 and GFP_(GAA TTC)560.
Correct integrants were selected using 200mg/ml hygro-
mycin according to the manufacturer’s recommendations.
Individual hygromycin-resistant colonies were isolated
using cloning discs (Fisher), expanded and analyzed
for repeat size and GFP expression level. All constructs
were sequenced prior to as well as after establishing the
stable cell lines.
Cellculture
HEK293Flp-InT-Rex cells were cultured in DMEM
medium (Sigma) supplemented with 10% FBS, 2mM
L-glutamine, 100U each of penicillin and streptomycin,
200mg/ml hygromycin B and 5mg/ml of blastocidin
(Invitrogen). Cells were grown at 378Ci n5 %C O 2.
Transfection of HEK293Flp-InT-Rex cells was carried
out using Lipofectamine2000 (Invitrogen) in OptiMEM
medium (Invitrogen) according to the supplier’s instruc-
tions. GM16210 (FRDA, (GAA TTC)580/580), GM15850
(FRDA, (GAA TTC)650/1030) and GM15851 (unaﬀected
control) lymphoblast cells were propagated in RPMI
1640 medium with 2mM L-glutamine, 15% FBS and
100U of penicillin and streptomycin at 378Ci n5 %C O 2.
PCR andqRT-PCR
Ampliﬁcation of long GAA TTC repeats was carried out
using previously described primers (2500F, 629) and con-
ditions (1). PCR products were cleaved using appropriate
restriction endonucleases and puriﬁed using agarose gel
electrophoresis (Qiagen).
The length of the GAA TTC tract integrated into
the HEK293Flp-InT-Rex cell lines was analyzed using
intronic primers 50CTTCCCTTTACACAACGTTTGG
GTT30 and 50GTACTGTTTGGATTCAGTGAGGGA
CT30. The level of GFP expression was determined using
quantitative reverse transcription PCR (qRT-PCR) with
primers complementary to exons 1 and 2 of this gene
(50GCGACGTAAACGGCCACAAGTT30;5 0ATGCCC
TTCAGCTCGATGCGGT30). The same primer pair
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QRT-PCR was carried out using a Stratagene Mx3005P
system and Brilliant II SYBR Green QPCR Master
Mix (Stratagene). In the qRT-PCR experiments,
GAPDH was used for normalization (primers 50GAA
GGTGAAGGTCGGAGTC30 and 50GAAGATGGTG
ATGGGATTTC30). All qRT-PCR analyses were carried
under the identical conditions of 958C for 20s, 558C for
30s and 728C for 1min; 40 cycles. Reverse transcription
PCR to analyze splicing of the GFP mRNA was modiﬁed
by extending the elongation step of the reaction to 5min.
Total RNA was isolated using PureLink
TM Micro-
to-Midi
TM Total RNA Puriﬁcation System (Invitrogen).
Genomic DNA was extracted with a GFX Genomic DNA
Puriﬁcation Kit (GE Healthcare).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described (9). For each
immunoprecipitation experiment, the amount of lysate
corresponding to 25–50mg of total DNA was incu-
bated with one of the following antibodies: anti-H3K9ac
(07-352), anti-H3K14ac (07-353), anti-H4K5ac (07-327),
anti-H4K8ac (07-328) and anti-H3K9me3 (17-625). All
antibodies were from Upstate Biotechnology/Millipore.
Samples were quantitated in triplicate by quantitative
PCR (qPCR) using the standard curve method. The pri-
mers used in this study were: for the region upstream of
the GAA TTC repeats in the GFP intron 50AATAGC
CTCCTGACCACAGATCCTT30 and 50CCATGTGAC
ATCTAGCCCGCA30; for the region downstream of the
GAA TTC repeats in the GFP intron, 50ACAGCAAAG
ACTGGAGCAACCCAT30 and 50CCCCATGAGAACC
CACAGTGTT30; and, for GAPDH, 50CACCGTCAAG
GCTGAGAACG30 and 50ATACCCAAGGGAGCCAC
ACC30. Statistical calculations were conducted using
SigmaPlot 2000.
RESULTS
Constructionof areporter minigene containing long,
intronic GAA TTC repeats
Since expanded GAA TTC repeats are located in intron
1 of the FXN gene,  1.5kb downstream of the ﬁrst exon,
we constructed a set of reporter minigenes based on a
eukaryotic variant of the GFP gene, with diﬀerent num-
bers of GAA TTC repeats in an artiﬁcial intron derived
from the rat Pem1 gene (31) (Figure 1). Repeats present
in GFP intron 1 are located 1.2kb from the exon/intron
junction. The minigenes were integrated by site-speciﬁc
recombination into the genome of the HEK293Flp-
InT-Rex cell line (see Materials and methods section).
The use of identical sites of integration for diﬀerent con-
structs allows for direct comparison between cell lines,
eliminating any potential bias resulting from random
integration events in diﬀerent chromosomal contexts.
Four cell lines were created that diﬀer in the
number of repeats present in the intron of the GFP
gene: GFP_(GAA TTC)560, GFP_(GAA TTC)270,
GFP_(GAA TTC)70 and a control cell line without
repeats (GFP_(GAA TTC)0). In all cases, the expression
of the GFP minigene is under the control of the tetracy-
cline inducible CMV promoter, with the tetracycline
repressor encoded in the genome of the HEK293Flp-
InT-Rex cells (Figure 1).
Long GAA TTC repeats are inherently unstable during
propagation in prokaryotic cells (32–35). Even short-term
culturing of cells containing plasmids with tracts longer
than  (GAA TTC)100 repeats leads to signiﬁcant
deletions within the repetitive sequence (32,33). In our
experiments, 40–50% of plasmids designed to contain
the (GAA TTC)270 insert and >90% of plasmids intended
to harbor the (GAA TTC)560 tract resulted in deleted
repeats after a short culture ( 15 generations) in
Escherichia coli HB101. However, the remaining 10% of
the undeleted plasmid (in the case of the (GAA TTC)560
tract) was suﬃcient for site-speciﬁc integration into the
HEK293Flp-InT-Rex genome (Supplementary Figure 1).
The size of GAA TTC repeats in genome-integrated mini-
genes was determined using PCR. In the majority of cases,
no changes in repeat size were observed during the inte-
gration process. We detected only one spontaneous,
large deletion (from 560 to 70 GAA TTC repeats) in the
15 individual clones we analyzed (Figure 2A, lane 5).
Prior studies suggest that the expanded GAA TTC
repeats in the intron 1 of the FXN gene do not inﬂuence
the splicing of the FXN pre-mRNA (18). On the other
Figure 1. Schematic diagram of the FXN and GFP genes containing
intronic GAA TTC repeats. (A) Structure of the FXN gene (50-region)
indicating the position of the trinucleotide repeats within intron 1.
Expansions longer than (GAA TTC)66 repeats lead to FRDA. Bu
and Bh designate recognition sites for Bsu36I and BssHII restriction
enzymes, respectively. These endonucleases were used to clone
GAA TTC tracts into the GFP intron. (B) Structures of the
GFP_(GAA TTC) minigenes. The GFP gene, expressed under control
of the CMV promoter and the tetracycline operator/repressor (TetO2),
was divided into two exons separated by a 1.7-kb intron. The
GAA TTC tracts of diﬀerent lengths (0, 70, 270 and 560 repeats)
were cloned into the Bsu36I and BssHII restriction sites 1.2kb from
the 50-end of the intron 1. These minigenes were site-speciﬁcally
integrated into the HEK293Flp-InT-Rex cells creating a set of
GFP_(GAA TTC) reporter cell lines harboring diﬀerent numbers
of GAA TTC repeats.
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GAA TTC repeats, are known to aﬀect splicing and pre-
mRNA processing when inserted into the intron of repor-
ter minigenes (36,37). Therefore, we analyzed whether the
GFP_(GAA TTC)560 mRNA is properly processed.
Reverse transcription PCR showed a single 325-bp band
corresponding to the predicted spliced product between
exons 1 and 2 of the GFP gene (Figure 2B). Using PCR
conditions allowing for ampliﬁcation of long cDNA frag-
ments, we were unable to detect any additional mRNA
resulting from aberrant or incomplete splicing of the
GAA TTC containing GFP intron (e.g. mRNA with non-
spliced intron; data not shown). These studies demon-
strate that long GAA TTC repeats can be integrated
into the genome of human cells and, when located in an
intron, these repeats do not interfere with splicing pattern
of our GFP reporter minigene. We cannot entirely exclude
a possibility that potential aberrant splicing products are
unstable, thus beyond our detection threshold.
Stable transmission of thelongGAA TTCrepeats
Long GAA TTC tracts have been shown to exhibit
both intergenerational and somatic instability in human
cells (38–40) which can impose a serious challenge to gen-
erate a reliable cellular model of any repeat expansion
disorder. Since transcription through repeats is one of
the most potent inducers of their instability (41–44),
we analyzed whether transcription can inﬂuence the
stability of the (GAA TTC)560 tract. We cultured the
GFP_(GAA TTC)560 cell line for 5, 10 and 20 passages
(one passage   2.3 population doublings) in the presence
(transcription on) and in the absence (transcription oﬀ)
of tetracycline (0.1mg/ml). Repeat length analyses revealed
a very strong eﬀect of transcription on the GAA TTC
tract instability (Figure 3). Similar to cultured human lym-
phocytes, a strong bias for contractions was observed (38).
Culturing the cells for only ﬁve passages resulted in >50%
reduction of the amount of the full-length (GAA TTC)560
insert (Figure 3). After 20 passages, <20% of the PCR
products contained GAA TTC tract of the original
length. However, we did not observe signiﬁcant
(GAA TTC)560 tract instability in the absence of tran-
scription (Figure 3). Although transcription of the
GFP_(GAA TTC)560 minigene is signiﬁcantly reduced
compared to the GFP_(GAA TTC)0 control construct
(see below), these results demonstrate that even relatively
low levels of transcription strongly stimulate the instabil-
ity of long GAA TTC repeats. Therefore, to maintain
stability of the GFP_(GAA TTC)560 minigene, we
blocked reporter gene expression by culturing in the
absence of tetracycline.
Long GAA TTC repeatsinduce transcriptional silencing
ofthe reporter gene
To determine whether GAA TTC repeats located in
the intron of our reporter minigene eﬀectively silence
its expression, we used quantitative RT-PCR to measure
the level of GFP mRNA in the GFP_(GAA TTC)70,
GFP_(GAA TTC)270 and GFP_(GAA TTC)560 cell lines
relatively to the GFP mRNA detected in GFP_
(GAA TTC)0 cells. The longest tract of (GAA TTC)560
led to 4- to 5-fold reduction of the GFP mRNA
Figure 2. Integration of the GFP_(GAA TTC) minigenes into the
HEK293Flp-InT-Rex cells. (A) PCR analyses of lengths of the
GAA TTC repeats in the minigenes integrated into the HEK293Flp-
InT-Rex cells. (B) Analyses of splicing of the GFP mRNA using cDNA
PCR. The splicing product of the minigene containing 560 GAA TTC
repeats (lane 1) is identical to the splicing product of the
GFP_(GAA TTC)0 minigene (lane 2). Both the size and sequence ana-
lyses conﬁrmed the correct splicing pattern of the GFP mRNA exons.
Control reactions were conducted without reverse transcriptase (–RT)
or RNA template (–RNA).
Figure 3. Eﬀect of transcription on instability of the (GAA TTC)560
tract in GFP_(GAA TTC)560 minigene. Cell line harboring
GFP_(GAA TTC)560 minigene was cultured for 5, 10 and 20 passages
(12, 24 and 48 population doublings) in the presence or absence of
tetracycline (0.1mg/ml). Repeat region was ampliﬁed using PCR and
the lost of the full-length (GAA TTC)560 band (indicated by arrow-
head) quantitated. Asterisks indicate statistically signiﬁcant diﬀerences
(P<0.01).
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only mildly aﬀected ( 25% decrease as compared to the
GFP_(GAA TTC)0). Insertion of 70 intronic GAA TTC
repeats had no eﬀect on the minigene transcription level
(Figure 4A). We also analyzed the eﬀects of the
GAA TTC repeat tracts on GFP levels measuring
ﬂuorescence using a plate reader and by FACS
(Figure 4B and C). The GFP_(GAA TTC)560 cell line
exhibited 2.5-fold less ﬂuorescence than cells harboring
the GFP_(GAA TTC)0. In contrast, GFP ﬂuorescence
detected in the cells expressing minigenes containing
70 and 270 GAA TTC repeats was not statistically dif-
ferent from the ﬂuorescence observed in the control
GFP_(GAA TTC)0 cells.
In summary, we demonstrated that (GAA TTC)560
located in the intron of the reporter gene signiﬁcantly inhi-
bits the expression of the minigene. The level of transcrip-
tional silencing observed for the GFP_(GAA TTC)560
reporter is similar to the transcriptional inhibition found
in FRDA patients. These results show that long intronic
GAA TTC repeats, isolated from their natural chromo-
somal and FXN gene contexts, are suﬃcient to induce
molecular consequences typical of the GAA TTC expan-
sions in the FRDA cells.
Gene silencing is induced by heterochromatin-specific
histone modifications
Since transcriptional silencing of pathological FXN alleles
is associated with pronounced changes in the acetylation
and methylation of histones present in the vicinity of
expanded GAA TTC repeats (9,23,24), to validate our
reporter construct, we analyzed histone modiﬁcations
in the regions immediately upstream and downstream of
the GAA TTC tracts in the GFP_(GAA TTC)0 and
GFP_(GAA TTC)560 cell lines. ChIP followed by qPCR
(Figure 5) revealed that acetylation of histone H3 lysine 9
and 14 (H3K9 and H3K14) in the region immediately
Figure 4. Long intronic GAA TTC repeats inhibit GFP expression.
(A) Results of the qRT-PCR analysis of the GFP mRNA expression
in four cell lines harboring 70, 270 and 560 repeats relative to the
GFP_(GAA TTC)0 cell line without GAA TTC repeats in the GFP
gene. (B) Analysis of the GFP expression using ﬂuorescence activated
cell sorter (FACS). Approximately 50000 cells for each cell line were
analyzed. HEK293Flp-InT-Rex cells (white) were used as a control.
(C) Analysis of the GFP expression using a ﬂuorescence plate reader.
Data are collected from duplicate analyses of two 96-well plates per
cell line.
Figure 5. Histone modiﬁcations induced by long GAA TTC repeats.
Chromatin modiﬁcations were analyzed in the GFP_(GAA TTC)560
and GFP_(GAA TTC)0 cell lines using the ChIP assay. Antibodies
speciﬁc for acetylation and trimethylation of diﬀerent lysine residues
in human histones H3 and H4 were used. The relative recovery was
determined using qPCR in relation to the GAPDH using primer pairs
for regions immediately upstream (A) and downstream (B) of the
GAA TTC repeats. Recovery of the GFP_(GAA TTC)0 for each anti-
body was set to the value of 100. Error bars indicate standard deviation
from at least two independent ChIP experiments quantitated in tripli-
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GFP_(GAA TTC)560 cells compared to the cells without
the repeats. Similarly, levels of acetylation of H4K5
and H4K8 were reduced in the vicinity of long repeats.
In addition, changes in H3K9 acetylation were accom-
panied by a 3-fold increase in trimethylation of K9
(Figure 5A). Analogous chromatin changes were detected
in the region downstream of the GAA TTC repeats
(Figure 5B). Thus, posttranslational histone modiﬁcations
observed in the vicinity of the GAA TTC repeats in
GFP_(GAA TTC)560 minigene are consistent with chro-
matin changes observed in the FXN gene in FRDA cells.
GFP_(GAA TTC)560 minigene expression is enhanced
by specific inducers ofFXN transcription
A number of compounds have been shown to relieve the
transcriptional silencing of the mutated FXN gene in
FRDA cells, including histone deacetylase inhibitors
(HDACi) (9). We analyzed the eﬀects of diﬀerent com-
pounds on the expression of the GFP_(GAA TTC)560
and GFP_(GAA TTC)0 minigenes. For comparison,
the inﬂuence of these compounds on FXN expression was
determined in the human lymphoblast cell lines GM16210
and GM15850 which were derived from FRDA patients as
well as in a control cell line GM15851 derived from an
unaﬀected individual. Four HDAC inhibitors, HDACi
106 [N1-(2-aminophenyl)-N7-p-tolylheptanediamide (25),
HDACi 4b (N1-(2-aminophenyl)-N7-phenylheptanedia-
mide, (9)], the hydroxamic acids oxamﬂatin and SAHA
(suberoylanilide hydroxamic acid) signiﬁcantly increased
(P<0.05) the expression of the GFP_(GAA TTC)560
reporter  1.4- to 2.5-fold (Table 1). Also, these com-
pounds induced expression of the FXN gene harboring
expanded GAA TTC repeats in the two cell lines derived
from FRDA patients (P<0.05). The two benzamides
HDACi 106 and 4b which had the most positive eﬀect in
FRDA cells also demonstrated the largest increases in
expression of the GFP_(GAA TTC)560 minigene.
Importantly, with the exception of SAHA, stimulation of
expression was speciﬁc to genes harboring GAA TTC
repeats, since these compounds did not aﬀect expression
of the GFP_(GAA TTC)0 control minigene or expression
of the FXN gene in the control GM15851 cell line
(data not shown). Four other compounds tested, splito-
micin, resveratrol, nicotinamide and scriptaid had no
inﬂuence on the expression of the GFP_(GAA TTC)560
and GFP_(GAA TTC)0 minigenes or on FXN gene tran-
scription. Hence, similarities in the response to diﬀerent
compounds, strongly support a common mechanism of
transcriptional silencing of expanded FXN genes and the
GFP_(GAA TTC)560 minigene.
DISCUSSION
A molecular model of FRDA was constructed, character-
ized and validated that recapitulates many of the molecu-
lar hallmarks of the mutated FXN allele. Also, this model
was adapted for high-throughput studies related to the
GAA TTC repeat-mediated transcriptional silencing and
drug discovery. Similar to the FXN gene, long GAA TTC
repeats inserted into the intron of the GFP gene signiﬁ-
cantly inhibit the expression of this reporter at both the
mRNA and protein levels, as inferred from decrease in
ﬂuorescence. Analogous to the FRDA cells, silencing is
linked to epigenetic changes in the vicinity of the expanded
repeats. Moreover, the chromatin modiﬁcations observed
in cells carrying the GFP_(GAA TTC)560 minigene are
strikingly similar to the posttranslational histone modiﬁ-
cations found in the FXN gene harboring an expanded
GAA TTC tract. Finally, we demonstrated that the
GAA TTC-induced transcriptional silencing can be par-
tially alleviated by the same compounds shown to stimu-
late FXN expression in human cell lines.
Long pathogenic GAA TTC repeats, isolated from
their natural chromosomal context of the FXN gene,
are capable of inducing posttranslational changes in
chromatin and eﬃciently inhibit expression of the
reporter gene. Hence, the GAA TTC silencing eﬀect
Table 1. Eﬀect of selected compounds on the GFP_(GAA TTC)560 minigene and FXN gene expression
Compound Concentration Increase of
GFP_(GAA TTC)560
expression (%)
SD (%) Eﬀect on FXN level
in FRDA cell lines (%)
SD
a (%)
DMSO 0.1% 100 8 100 7
 HDACi 106
b 10mM 243 11 265 19
 HDACi 4b
b 10mM 194 9 251 18
 Oxamﬂatin 1mM 193 8 154 18
 SAHA
b 2.5mM 139 23 168 14
Splitomicin 20mM 103 6 91 11
Resveratrol 20mM 99 2 94 19
Nicotinamide 2mM 89 9 106 17
Scriptaid 1mM7 7 2 1 9 3 2 5
  Trichostatin A
b 0.05mM 85 6 124 11
GFP expression was measured using a ﬂuorescence plate reader. Levels of the FXN mRNA in GM16210 and GM15850 cell lines were determined
using qRT-PCR. Changes of expression are presented relative to the eﬀect of 0.1% DMSO.
aHigh SD values result from the inclusion of qRT-PCR data obtained using two diﬀerent FRDA cell lines.
bThe inﬂuence of these compounds on FXN expression and/or frataxin levels was reported previously.
 Compounds signiﬁcantly (P<0.05) stimulating expression of both the GFP_(GAA TTC)560 minigene and the mutated FXN gene.
  Trichostatin A had an inhibitory eﬀect on the GFP_(GAA TTC)560 minigene expression (P<0.05), while it did not signiﬁcantly aﬀect FXN
transcription in the lymphoblast cell lines.
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intronic sequences and a promoter and is attributed to
the GAA TTC repeats per se.
Pattern of chromatin modiﬁcations observed in our
model cell line harboring 560 GAA TTC repeats is char-
acteristic for all FRDA cells and animal model systems
analyzed so far (9,23–25). Although the extent of histone
modiﬁcations observed in human lymphoblast cell lines,
primary lymphocytes from FRDA patients and the
GFP_(GAA TTC)560 minigene diﬀer, hypoacetylation of
H3K9, H3K14, H4K5 and H4K8 as well as increased
H3K9 trimethylation was consistently detected in the
vicinity of the expanded repeats (9). Additionally, similar
histone modiﬁcations were detected in human brain tissue
from two FRDA patients, particularly downstream of the
GAA TTC tract (23). The epigenetic changes were also
observed in brain tissues from transgenic mouse harboring
mutated FXN gene; however, the level of hypoacetylation
observed in the FRDA mouse was lower than in human
samples, most likely due to the relatively short GAA TTC
tracts ( 200 repeats) (23). Despite of a signiﬁcant diﬀer-
ence in the size of GAA TTC repeats between transgenic
mouse and human FRDA samples, decreased acetylation
and increased trimethylation of the H3K9 were consis-
tently found in both systems.
The GAA TTC repeats are one of the most abundant
microsatellites found in the human and mouse genomes
(45–48). More than 13 000 GAA TTC tracts spanning on
average 74bp/Mb have been identiﬁed in the human
genome with multiple loci containing polymorphic tracts
longer than 100bp (46–48). Length polymorphism of the
repeating sequences plays an important role in regulation
of expression and protein function providing a source of
both quantitative and qualitative phenotypic variation
(49–51). The repeat sequences located in a diﬀerent chro-
mosomal context may act as gene expression modiﬁers
via length-dependent epigenetic DNA and histone modi-
ﬁcations (52). Relatively short GAA TTC repeats,
inserted randomly into the mouse genome, confer variega-
tion of a transgene expression (22). Other trinucleotide
repeating sequences such as CTG CAG and CGG CCG,
which are expanded in certain human neurological
diseases (53), can alter chromatin status. Moderately
expanded (<200 copies) CGG CCG repeats in the
50-UTR of the fragile X mental retardation gene (FMR1)
may facilitate its increased transcription in patients with
fragile X-associated tremor/ataxia syndrome (FXTAS)
(54,55). On the other hand, large CGG CCG expansions
in this gene (>200 copies) are associated with histone
hypoacetylation and methylation of the adjacent CpG
islands resulting in transcriptional silencing of this gene
(56–58). Large expansions of the CTG CAG repeats
in the congenital form of myotonic dystrophy type I are
also associated with heterochromatin formation and CpG
island methylation (59). Expansions of both CTG CAG
and CGG CCG repeats also inﬂuence positioning and
stability of the nucleosomes in vitro and in vivo (60–63).
The GAA TTC repeats belong to the large group
of polypurine polypyrimidine (R Y) sequences that are
greatly overrepresented in the human genome (64).
Recent studies showed that nearly 3000R Y tracts
longer than 100bp and more than 800R Y sequences
longer that 250bp exist in the human genome (64). The
R Y tracts, including GAA TTC repeats, have a high
propensity to form triplex DNA structures (12,65,66).
These noncanonical DNA conformations can trigger
changes in gene expression either directly, by blocking
the progression of the transcriptional apparatus, or indi-
rectly, via the posttranslational chromatin modiﬁcations
(9,18,19,67).
Results of analyses conducted in vitro and in prokary-
otic cells indicated that tracts of 30–100 GAA TTC
repeats signiﬁcantly inhibit transcription through the
repeat region (14,18–21,67). In our molecular model of
FRDA, a tract of 270 GAA TTC repeats did not consid-
erably inhibit the expression of the reporter minigene ( 75
and 85% of the GFP_(GAA TTC)0 protein and mRNA
levels, respectively). This result is consistent with studies
conducted in FRDA patients and mouse models (68), thus
indicating that mammalian models of the GAA TTC-
induced transcriptional silencing are more relevant to
the mechanism of the disease than in vitro or prokary-
otic systems. Homozygous knock-in Frda
230/230GAA mice
expressed 66–83% of the wild-type levels of frataxin (68),
which is similar to the amount of GFP expressed in
the GFP_(GAA TTC)270 cells. As expected, insertion
of a substantially longer tract of the (GAA TTC)560
repeats signiﬁcantly reduced ( 45 and 20% of the
GFP_(GAA TTC)0 ﬂuorescence and mRNA levels,
respectively) the expression of the reporter gene as com-
pared to the GFP_(GAA TTC)0 cells.
The cloning and stable maintenance of long GAA TTC
repeats is a crucial step in the construction of reporter
genes containing expanded repeating sequences. Tracts
longer than 100 GAA TTC repeats frequently undergo
rapid deletions, particularly in plasmids cultivated in pro-
karyotic hosts during cloning procedures (19,32,33).
Interestingly, (GAA TTC)560 tracts were unstable even
in the context of genomic DNA. A weak stimulation
of transcription through the GAA TTC repeats led to
the destabilization of the repeats, whereas inhibition of
transcription resulted in complete stabilization of the
repeats. While transcription has been shown to stimulate
CTG CAG, GAA TTC and CGG CCG repeat insta-
bilities in prokaryotic systems (33,41,42), the eﬀect of
transcription was demonstrated only for CTG CAG
repeats in eukaryotic cells (43,44). Transcription-induced
GAA TTC repeat instability observed in our model
system has important implications for the progressive
somatic GAA TTC repeat instability observed in FRDA
patients (39,40,69). Transcription has been postulated
recently to be a major factor inﬂuencing CTG CAG
repeat instability in nondividing neuronal cells (43,44).
Perhaps the same mechanism is responsible for somatic
GAA TTC instabilities observed in dorsal root ganglia
(DRG) cells of the FRDA patients (39).
Studies on the molecular pathogenesis and potential
therapeutic strategies for FRDA are generally conducted
using lymphoblast cell lines and primary cells derived
from FRDA patients. In addition, mouse models are
employed to elucidate various aspects of the FRDA devel-
opment. These model systems are invaluable in the
6062 Nucleic Acids Research, 2008, Vol. 36, No. 19analyses of selected, speciﬁc processes related to the dis-
ease etiology. On the other hand, they cannot be used
in the comprehensive, high-throughput screens in search
for new treatment strategies. High-throughput cell-based
approaches require assays that can be quantitatively
monitored using rapid and sensitive reporter systems.
Two research groups created FRDA reporter cell lines
in the search for compounds capable of alleviating
GAA TTC-induced silencing. Sarsero et al. (29) generated
an in-frame fusion between human FXN gene and the
GFP gene. This construct, however, does not contain
expanded GAA TTC repeats, which is the hallmark of
the FRDA pathogenesis and a primary genetic defect lead-
ing to the disease. The fusion reporter harbors only 6
GAA TTC repeats and therefore it only allows for the
identiﬁcation of molecules that act on the wild-type pro-
moter and not on the repeats. A second reporter cell
line generated by Hebert and coworkers (30) used frag-
ments of the FXN gene containing 15 and 148 GAA TTC
repeats fused to the GFP reporter gene. In this construct,
the GAA TTC repeats were located in the 50-UTR of
the reporter; consequently, the inhibition of the reporter
gene expression likely results from the interference with
translation rather than with transcription.
No eﬀective treatment is available for FRDA at the
present time. Histone deacetylase inhibitors are currently
the most promising compounds for targeting the FXN
gene silencing (9,25). We demonstrated that HDACIs,
eﬀective in induction of the frataxin expression, are also
capable of stimulation of the GFP_(GAA TTC)560 mini-
gene expression. Hence, this molecular model of FRDA
can be utilized to analyze large collections of compounds,
in a high-throughput setting, to discover new candidate
drugs capable of alleviating the GAA TTC-mediated
transcriptional repression.
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